Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy in a combination regimen used ...

Mark Strassmann is CBS News' senior national correspondent based in Atlanta. He covers a wide range of stories, including space exploration. Strassmann is also the senior national correspondent for ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.